Nemvaleukin increased tumor-infiltrating CD4+ and CD8+ T cells, promoted the expansion of non-regulatory T-cell populations, and significantly slowed tumor growth compared to controls and recombinant human IL-2 (rhIL-2) treatment. Here, CD8A is linked to neoplasm.